Current understanding of HIV-associated neurocognitive disorders pathogenesis

Current Opinion in Neurology

Volumn 24, Issue 3, 2011, Pages 275-283

  Gannon, Patrick ^b   Khan, Muhammad Z ^a   Kolson, Dennis L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

antiretroviral therapy; cognitive dysfunction; HIV; HIV associated neurocognitive disorders; inflammation

Indexed keywords

COCAINE; METHAMPHETAMINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AFRICA; AGING; ARTICLE; BRAIN INFECTION; DRUG ABUSE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROTOXICITY; PATHOGENESIS; VIRUS REPLICATION;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; CENTRAL NERVOUS SYSTEM; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; SUBSTANCE-RELATED DISORDERS; VIRUS REPLICATION;

EID: 79955612804     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834695fb     Document Type: Article

References (155)

1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIVassociated neurocognitive disorders. Neurology 2007; 69:1789-1799. (Pubitemid 350059308)
2. Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry 2008; 20:33-47. (Pubitemid 351210470)
3. Kaul M. HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr Opin Neurol 2009; 22:315-320.
4. McArthur JC, Steiner J, Sacktor N, et al. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010; 67:699-714.
5. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8:136-142. (Pubitemid 34520894)
6. McArthur JC, McDermott MP, McClernon D, et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004; 61:1687-1696. (Pubitemid 39463427)
7. Nath A, Schiess N, Venkatesan A, et al. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 2008; 20:25-31. (Pubitemid 351196197)
8. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010; 75:2087-2096.
9. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17:3-16.
10. Letendre SL, Ellis RJ, Ances BM, et al. Neurologic complications of HIV disease and their treatment. Top HIV Med 2010; 18:45-55.
11. Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 2011; 8:54-61.
12. Glass JD, Fedor H, Wesselingh SL, et al. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995; 38:755-762.
13. Adle-Biassette H, Chretien F, Wingertsmann L, et al. Neuronal apoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage. Neuropathol Appl Neurobiol 1999; 25:123-133. (Pubitemid 29221762)
14. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009; 17:118-123.
15. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23:929-939.
16. Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009; 207:524-529.
17. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
18. Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/ HCV coinfection with C-reactive protein levels: the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48:142-148.
19. Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316-322.
20. van Vonderen MG, Hassink EA, van Agtmael MA, et al. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis 2009; 199:1186-1194.
21. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371. (Pubitemid 44924494)
22. Wallet MA, Rodriguez CA, Yin L, et al. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 2010; 24:1281-1290.
23. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006; 7:235-239.
24. Brenchley JM, Schacker TW, Ruff LE, et al. CD4\+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759. (Pubitemid 39299461)
25. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-1185.
26. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4\+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 2008; 22:2035-2038.
27. Grovit-Ferbas K, Harris-White ME. Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction. Immunol Res 2010; 48:40-58.
28. Kraft-Terry SD, Buch SJ, Fox HS, et al. A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron 2009; 64:133-145.
29. Kaul M, Lipton SA. Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J Neuroimmune Pharmacol 2006; 1:138-151. (Pubitemid 44257489)
30. Boisse L, Gill MJ, Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin 2008; 26:799-819. (Pubitemid 352037443)
31. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004; 18 (Suppl 1):S75-S78. (Pubitemid 38365909)
32. Anthony IC, Ramage SN, Carnie FW, et al. Influence of HAART on HIVrelated CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005; 64:529-536. (Pubitemid 40781156)
33. Cherner M, Masliah E, Ellis RJ, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002; 59:1563-1567. (Pubitemid 35387063)
34. Bell JE. An update on the neuropathology of HIV in the HAART era. Histopathology 2004; 45:549-559. (Pubitemid 40029814)
35. Everall IP, Hansen LA, Masliah E. The shifting patterns of HIV encephalitis neuropathology. Neurotox Res 2005; 8:51-61.
36. Everall I, Vaida F, Khanlou N, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 2009; 15:360-370.
37. Gras G, Chretien F, Vallat-Decouvelaere AV, et al. Regulated expression of sodium-dependent glutamate transporters and synthetase: a neuroprotective role for activated microglia and macrophages in HIV infection? Brain Pathol 2003; 13:211-222. (Pubitemid 36460821)
38. Anthony IC, Bell JE. The neuropathology of HIV/AIDS. Int Rev Psychiatry 2008; 20:15-24. (Pubitemid 351196199)
39. McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virusassociated dementia: an evolving disease. J Neurovirol 2003; 9:205-221. (Pubitemid 36656454)
40. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5:69-81. (Pubitemid 40070332)
41. Kolson DL, Gonzalez-Scarano F. HIV-1 and dementia. J Clin Invest 2000; 106:11-13.
42. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410:988-994. (Pubitemid 32335850)
43. Swindells S, Zheng J, Gendelman HE. HIV-associated dementia: new insights into disease pathogenesis and therapeutic interventions. AIDS Patient Care STDS 1999; 13:153-163. (Pubitemid 29155983)
44. Anderson E, Zink W, Xiong H, et al. HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir ImmuneDefic Syndr 2002; 31 (Suppl 2):S43-54. (Pubitemid 35190558)
45. Fischer-Smith T, Croul S, Adeniyi A, et al. Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy. Am J Pathol 2004; 164:2089-2099.
46. Conant K, Garzino-Demo A, Nath A, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 1998; 95:3117-3121. (Pubitemid 28135864)
47. Chang L, Ernst T, St Hillaire C, et al. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther 2004; 9:431-440. (Pubitemid 38878759)
48. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS 1992; 6:461-465.
49. Brew BJ, Dunbar N, Pemberton L, et al. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis 1996; 174:294-298. (Pubitemid 26251414)
50. Enting RH, Foudraine NA, Lange JM, et al. Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine. J Neuroimmunol 2000; 102:216-221.
51. McArthur JC, Nance-Sproson TE, Griffin DE, et al. The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study. Neurology 1992; 42:1707-1712.
52. Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 1991; 29:202-209.
53. Heyes MP, Ellis RJ, Ryan L, et al. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. Brain 2001; 124 (Pt 5):1033-1042. (Pubitemid 32458515)
54. Brew BJ, Corbeil J, Pemberton L, et al. Quinolinic acid production is related to macrophage tropic isolates of HIV-1. J Neurovirol 1995; 1:369-374.
55. Achim CL, Heyes MP, Wiley CA. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest 1993; 91:2769-2775. (Pubitemid 23182534)
56. Griffin DE, Wesselingh SL, McArthur JC. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol 1994; 35:592-597.
57. Genis P, Jett M, Bernton EW, et al. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophageastroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 1992; 176:1703-1718.
58. Haughey NJ, Cutler RG, Tamara A, et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 2004; 55:257-267. (Pubitemid 38167003)
59. Schifitto G, Yiannoutsos CT, Ernst T, et al. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology 2009; 73:1975-1981.
60. Gelbard HA, Nottet HS, Swindells S, et al. Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol 1994; 68:4628-4635. (Pubitemid 24183060)
61. Eden A, Price RW, Spudich S, et al. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007; 196:1779-1783. (Pubitemid 351411938)
62. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52:607-613. (Pubitemid 29075612)
63. Gray F, Chretien F, Vallat-Decouvelaere AV, et al. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 2003; 62:429-440. (Pubitemid 36560185)
64. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008; 3:e2516.
65. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4\+ T cell depletion and viral replication in SIV infection. Science 1998; 280:427-431. (Pubitemid 28208163)
66. Brew BJ, Crowe SM, Landay A, et al. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 2009; 4:163-174.
67. Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 2007; 85:3036-3040. (Pubitemid 350057358)
68. Chang L, Wong V, Nakama H, et al. Greater than age-related changes in brain diffusion of HIV patients after 1 year. J Neuroimmune Pharmacol 2008; 3:265-274.
69. Montano M, Rarick M, Sebastiani P, et al. Gene-expression profiling of HIV-1 infection and perinatal transmission in Botswana. Genes Immun 2006; 7:298-309. (Pubitemid 43871530)
70. Isaacman-Beck J, Hermann EA, Yi Y, et al. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol 2009; 83:8208-8220.
71. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-852. (Pubitemid 43363943)
72. Chittiprol S, Kumar AM, Satishchandra P, et al. Progressive dysregulation of autonomic and HPA axis functions in HIV-1 clade C infection in South India. Psychoneuroendocrinology 2008; 33:30-40.
73. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005; 40:336-343. (Pubitemid 41533075)
74. Brown BK, Wieczorek L, Sanders-Buell E, et al. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008; 375:529-538.
75. Santra S, Korber BT, Muldoon M, et al. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci USA 2008; 105:10489-10494.
76. Brown BK, Darden JM, Tovanabutra S, et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01-AE, and CRF02-AG, for the development and assessment of candidate vaccines. J Virol 2005; 79:6089-6101. (Pubitemid 40617214)
77. Rao VR, Sas AR, Eugenin EA, et al. HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci 2008; 28:10010-10016.
78. Yepthomi T, Paul R, Vallabhaneni S, et al. Neurocognitive consequences of HIV in southern India: a preliminary study of clade C virus. J Int Neuropsychol Soc 2006; 12:424-430. (Pubitemid 43970908)
79. Robertson K, Liner J, Hakim J, et al. NeuroAIDS in Africa. J Neurovirol 2010; 16:189-202.
80. Sacktor N, Nakasujja N, Skolasky RL, et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 2009; 49:780-786.
81. Sacktor N, Nakasujja N, Skolasky R, et al. Antiretroviral therapy improves cognitive impairment in HIV\+ individuals in sub-Saharan Africa. Neurology 2006; 67:311-314. (Pubitemid 44305421)
82. Lawler K, Mosepele M, Ratcliffe S, et al. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc 2010; 13:15.
83. Liner KJ 2nd, Ro MJ, Robertson KR. HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep 2010; 7:85-91.
84. Hauser KF, El-Hage N, Stiene-Martin A, et al. HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem 2007; 100:567-586. (Pubitemid 46095610)
85. Nath A. Human immunodeficiency virus-associated neurocognitive disorder: pathophysiology in relation to drug addiction. Ann N Y Acad Sci 2010; 1187:122-128.
86. Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci 2010 [Epub ahead of print].
87. Beyrer C, Wirtz AL, Baral S, et al. Epidemiologic links between drug use and HIV epidemics: an international perspective. J Acquir Immune Defic Syndr 2010; 55 (Suppl 1):S10-S16. This review summarizes the international risks for HIV spread due to the expansion of intravenous drug abuse, with implications for worldwide spread of different HIV subtypes.
88. Bell JE, Arango JC, Anthony IC. Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illicit drugs. J Neuroimmune Pharmacol 2006; 1:182-191. (Pubitemid 44257492)
89. Anthony IC, Arango JC, Stephens B, et al. The effects of illicit drugs on the HIV infected brain. Front Biosci 2008; 13:1294-1307. (Pubitemid 351594711)
90. Martinez AJ, Sell M, Mitrovics T, et al. The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases. Pathol Res Pract 1995; 191:427-443.
91. Quan VM, Minh NL, Ha TV, et al. Mortality and HIV transmission among male Vietnamese injection drug users. Addiction 2011; 106:583-589.
92. Jevtovic D, Vanovac V, Veselinovic M, et al. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART. Biomed Pharmacother 2009; 63:561-565.
93. Marcondes MC, Flynn C, Watry DD, et al. Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virusinfected monkeys. Am J Pathol 2010; 177:355-361.
94. Rogers TJ. Immunology as it pertains to drugs of abuse, AIDS and the neuroimmune axis: mediators and traffic. J Neuroimmune Pharmacol 2011; 6:20-27.
95. Marcario JK, Riazi M, Adany I, et al. Effect of morphine on the neuropathogenesis of SIVmac infection in Indian rhesus macaques. J Neuroimmune Pharmacol 2008; 3:12-25.
96. Perez-Casanova A, Noel RJ Jr, Rivera-Amill V, et al. Morphine-mediated deterioration of oxidative stress leads to rapid disease progression in SIV/ SHIV-infected macaques. AIDS Res HumRetroviruses 2007; 23:1004-1007. (Pubitemid 47492341)
97. Hauser KF, El-Hage N, Buch S, et al. Impact of opiate-HIV-1 interactions on neurotoxic signaling. J Neuroimmune Pharmacol 2006; 1:98-105. (Pubitemid 44257504)
98. Guo CJ, Li Y, Tian S, et al. Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor. J Investig Med 2002; 50:435-442. (Pubitemid 35278684)
99. Ho WZ, Guo CJ, Yuan CS, et al. Methylnaltrexone antagonizes opioidmediated enhancement of HIV infection of human blood mononuclear phagocytes. J Pharmacol Exp Ther 2003; 307:1158-1162.
100. Peterson PK, Gekker G, Hu S, et al. Cannabinoids and morphine differentially affect HIV-1 expression in CD4(\+) lymphocyte and microglial cell cultures. J Neuroimmunol 2004; 147:123-126. (Pubitemid 38114961)
101. Dave RS, Khalili K. Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system. J Cell Biochem 2010; 110:834-845.
102. Li Y, Wang X, Tian S, et al. Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis 2002; 185:118-122. (Pubitemid 34043026)
103. Kumar R, Torres C, Yamamura Y, et al. Modulation by morphine of viral set point in rhesus macaques infected with simian immunodeficiency virus and simian-human immunodeficiency virus. J Virol 2004; 78:11425-11428. (Pubitemid 39299687)
104. Happel C, Kutzler M, Rogers TJ. Opioid-induced chemokine expression requires NF-{kappa}B activity: the role of PKC{zeta}. J Leukoc Biol 2011; 89:301-309.
105. Happel C, Steele AD, Finley MJ, et al. DAMGO-induced expression of chemokines and chemokine receptors: the role of TGF-beta1. J Leukoc Biol 2008; 83:956-963. (Pubitemid 351959876)
106. Gekker G, Hu S, Wentland MP, et al. Kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells. J Pharmacol Exp Ther 2004; 309:600-606. (Pubitemid 38542613)
107. Peterson PK, Gekker G, Lokensgard JR, et al. Kappa-opioid receptor agonist suppression of HIV-1 expression in CD4\+ lymphocytes. Biochem Pharmacol 2001; 61:1145-1151. (Pubitemid 32285481)
108. Donahoe RM. Multiple ways that drug abuse might influence AIDS progression: clues from a monkey model. J Neuroimmunol 2004; 147:28-32. (Pubitemid 38114942)
109. Ferris MJ, Mactutus CF, Booze RM. Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev 2008; 32:883-909.
110. Dhillon NK, Williams R, Peng F, et al. Cocaine-mediated enhancement of virus replication in macrophages: implications for human immunodeficiency virus-associated dementia. J Neurovirol 2007; 13:483-495.
111. Reynolds JL, Mahajan SD, Bindukumar B, et al. Proteomic analysis of the effects of cocaine on the enhancement of HIV-1 replication in normal human astrocytes (NHA). Brain Res 2006; 1123:226-236.
112. Conant K, Tornatore C, Atwood W, et al. In vivo and in vitro infection of the astrocyte by HIV-1. Adv Neuroimmunol 1994; 4:287-289. (Pubitemid 24325876)
113. ChurchillMJ, Wesselingh SL, Cowley D, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 2009; 66:253-258.
114. Vincendeau M, Kramer S, Hadian K, et al. Control of HIV replication in astrocytes by a family of highly conserved host proteins with a common Revinteracting domain (Risp). AIDS 2010; 24:2433-2442.
115. Nair MP, Mahajan SD, Schwartz SA, et al. Cocaine modulates dendritic cellspecific C type intercellular adhesion molecule-3-grabbing nonintegrin expression by dendritic cells in HIV-1 patients. J Immunol 2005; 174:6617-6626. (Pubitemid 40705622)
116. Nair MP, Saiyed ZM, Nair N, et al. Methamphetamine enhances HIV-1 infectivity in monocyte derived dendritic cells. J Neuroimmune Pharmacol 2009; 4:129-139.
117. Fiala M, Eshleman AJ, Cashman J, et al. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol 2005; 11:281-291. (Pubitemid 41122416)
118. Berger JR, Avison M. The blood brain barrier in HIV infection. Front Biosci 2004; 9:2680-2685.
119. Zhang L, Looney D, Taub D, et al. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol 1998; 4:619-626. (Pubitemid 29042068)
120. Mahajan SD, Aalinkeel R, Sykes DE, et al. Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res 2008; 1203:133-148.
121. Gurwell JA, Nath A, Sun Q, et al. Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience 2001; 102:555-563. (Pubitemid 32171876)
122. Avison MJ, Nath A, Greene-Avison R, et al. Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol 2004; 10:223-232. (Pubitemid 39136617)
123. Chang L, Alicata D, Ernst T, et al. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 2007; 102 (Suppl 1):16-32. (Pubitemid 46328220)
124. Chang L, Cloak C, Patterson K, et al. Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol Psychiatry 2005; 57:967-974. (Pubitemid 40603079)
125. Berger JR, Nath A. HIV dementia and the basal ganglia. Intervirology 1997; 40:122-131. (Pubitemid 28021606)
126. Xu J, Ikezu T. The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol 2009; 4:200-212.
127. Ernst T, Chang L. Effect of aging on brain metabolism in antiretroviral-naive HIV patients. AIDS 2004; 18 (Suppl 1):S61-S67. (Pubitemid 38365907)
128. Cherner M, Ellis RJ, Lazzaretto D, et al. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS 2004; 18 (Suppl 1):S27-34. (Pubitemid 38365903)
129. Ances BM, Vaida F, Yeh MJ, et al. HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis 2010; 201:336-340.
130. Anthony IC, Bell J. Neuropathological findings associated with long-term HAART. In: Paul RH, Sacktor NC, Valcour V, Tashima KT, editors. HIV and the brain. Edinburgh: Humana Press; 2009. pp. 29-47.
131. Tisch S, Brew B. Parkinsonism in HIV-infected patients on highly active antiretroviral therapy. Neurology 2009; 73:401-403.
132. Green DA, Masliah E, Vinters HV, et al. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 2005; 19:407-411. (Pubitemid 40446187)
133. Anthony IC, Ramage SN, Carnie FW, et al. Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active antiretroviral therapy. Acta Neuropathol 2006; 111:529-538. (Pubitemid 43778957)
134. Achim CL, Adame A, Dumaop W, et al. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol 2009; 4:190-199.
135. Brew BJ, Pemberton L, Blennow K, et al. CSF amyloid beta42 and Tau levels correlate with AIDS dementia complex. Neurology 2005; 65:1490-1492. (Pubitemid 41552790)
136. Brew BJ. Benefit or toxicity from neurologically targeted antiretroviral therapy? Clin Infect Dis 2010; 50:930-932.
137. Vehmas A, Lieu J, Pardo CA, et al. Amyloid precursor protein expression in circulating monocytes and brain macrophages from patients with HIVassociated cognitive impairment. J Neuroimmunol 2004; 157:99-110. (Pubitemid 39576643)
138. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 1998; 65:29-33. (Pubitemid 28302353)
139. Cardenas VA, Meyerhoff DJ, Studholme C, et al. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol 2009; 15:324-333.
140. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
141. Schweinsburg BC, Taylor MJ, AlhassoonOM, et al. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV\+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 2005; 11:356-364. (Pubitemid 41614515)
142. Zhou H, Gurley EC, Jarujaron S, et al. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Am J Physiol Gastrointest Liver Physiol 2006; 291:G1071-G1080. (Pubitemid 44904161)
143. Zhou H, Pandak WM Jr, Lyall V, et al. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol 2005; 68:690-700. (Pubitemid 41206022)
144. Dufer M, Neye Y, Krippeit-Drews P, et al. Direct interference of HIV protease inhibitors with pancreatic beta-cell function. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:583-590. (Pubitemid 38823991)
145. Schutt M, Zhou J, Meier M, et al. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. J Endocrinol 2004; 183:445-454. (Pubitemid 40057575)
146. Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001; 7:1327-1331. (Pubitemid 34007937)
147. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease: is this type 3 diabetes? J Alzheimers Dis 2005; 7:63-80. (Pubitemid 40387185)
148. Kroner Z. The relationship between Alzheimer's disease and diabetes: type 3 diabetes? Altern Med Rev 2009; 14:373-379.
149. Vidal F, Gutierrez F, Gutierrez M, et al. Pharmacogenetics of adverse effects due to antiretroviral drugs. AIDS Rev 2010; 12:15-30.
150. Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 28:357-365.
151. Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004; 56:416-423. (Pubitemid 39166561)
152. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
153. Patel K, Ming X, Williams PL, et al. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 2009; 23:1893-1901.
154. Joska JA, GouseH, PaulRH, et al. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 2010; 16:101-114.
155. Winston A, Duncombe C, Li PC, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after .48. weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010; 50:920-929.